Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 56.6% in June

Fortress Biotech, Inc. (NASDAQ:FBIOP) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totaling 4,938 shares, a decline of 56.6% from the May 31st total of 11,366 shares. Based on an average daily volume of 41,576 shares, the short-interest ratio is presently 0.1 days.

Fortress Biotech Trading Up 0.3%

Shares of FBIOP stock opened at $20.11 on Monday. The business’s 50 day moving average is $17.16 and its two-hundred day moving average is $13.76. Fortress Biotech has a 12-month low of $6.27 and a 12-month high of $21.43.

About Fortress Biotech

Fortress Biotech, Inc (NASDAQ: FBIOP) is a biopharmaceutical company that acquires, develops and commercializes innovative therapeutics for the treatment of patients with serious diseases. Operating as a biotech accelerator, Fortress Biotech partners with experienced management teams to advance products from early-stage discovery through regulatory approval and commercial launch. Its diversified portfolio spans multiple therapeutic areas, including oncology, rare diseases, dermatology, ophthalmology and neuromuscular disorders.

The company’s business model centers on establishing and funding product-centric subsidiary companies, each focused on a specific drug candidate or therapy.